Main Article Content

Richard Ian Ogilvie




At the Canadian Society of Pharmacology and Therapeutics Annual Meeting in Montreal on May 27, 2011 Richard Ian Ogilvie, Professor Emeritus of Medicine and Pharmacology at the
University of Toronto was invited to present a lecture regarding his 45 year career in clinical pharmacology in Canada. In the lecture he identified the people and events that shaped his accomplished career.

Abstract 83 | PDF Downloads 140


1. Ogilvie RI, Ruedy J. Adverse drug reactions during hospitalization. CMAJ 1967;97:1450-7.
2. Ogilvie RI, Ruedy J. An educational program in digitalis therapy. JAMA 1972;22:50-5.
3. Melville KI, Stehle RL Mercury diuresis. JPET 1928.
4. Zborowska-Sluis DT, Ogilvie RI, Klassen G. Reversal of hyperventilation-induced hyperlactatemia by acetazolamide. Respiratory Physiology 1970;10:417-24.
5. Grocott MPW, et al. Arterial blood gases and oxygen content in climbers on Mount Everest. NEJM2009;360:140-9.
6. Ogilvie RI, Ruedy J. Treatment of hypertension with hydrochlorothiazide and spironolactone. CMAJ 1969;101:591-4.
7. McLeod PJ, Ogilvie RI, Ruedy J. Metabolic and hypotensive effects of low and high doses of hydrochlorothiazide. Clin Pharmacol Therap 1970;11:733-9.
8. Ogilvie RI. Cardiovascular response to exercise under increasing doses of chlorthalidone. Europ. J Clin Pharmacol 1976;9:339-44.
9. Tweeddale MG, Ogilvie RI, Ruedy J. The antihypertensive and biochemical effects of chlorthalidone in essential hypertension. Clin Pharmacol Therap 1977;22:519-27.
10. Ogilvie RI, Piafsky KM, Ruedy J. Antihypertensive effect of increasing doses of spironolactone in normal renin hypertension. Clin Pharmacol Therap 1978;24:525-30.
11. Kreeft JH, Larochelle P, Ogilvie RI. Comparison of chlorthalidone and spironolactone in lowrenin hypertension. Can Med Assoc J 1983;128:31-4.
12. Kurtz TW. Chlorthalidone: Don’t call it “thiazide-like” anymore. Hypertension 2010; 56:335-37.
13. University Group Diabetes Program Study. Diabetes 1970;19:747-830.
14. Kaul S, Diamond GA. Is there clear and convincing evidence of cardiovascular risk with rosiglitazone? Clin Pharmacol Therap 2011;89:773-6.
15. Winterstein AG. Rosiglitazone and the risk of adverse cardiovascular outcomes. Clin Pharmacol Therap 2011;89:776-8.
16. Ogilvie RI, Klassen G. Metabolic effect and uptake of 3H-digoxin in the forearm of man. Clinical Science 1972;42:567-77.
17. Ogilvie RI. Antilipolytic effect of digoxin in the forearm of man. J Clin Endoc Metab 1973; 36:568-75.
18. Zinman B, Ogilvie RI. Acute effects of tolbutamide on forearm metabolism. J Clin EndocMetab 1972;35:299-306.
19. Ogilvie RI, Schlieper E. The effect of hydrochlorothiazide on venous reactivity in hypertensive man. Clin Phamacol Ther 1970; 11:589-94.
20. Nadeau JH, Ogilvie RI. Cardiovascular effects of acebutolol and hydrochlorothiazide in essential hypertension. Hypertension 1982; 4:320-4.
21. Kreeft JH, Langlois S, Ogilvie RI. Comparative trial of hydrochlorothiazide and indapamide in essential hypertension with forearm plethysmography. J Cardiovasc Pharmacol 1984;6:622-6.
22. Ogilvie RI, Nadeau JH, Lutterodt A. Vasodilator capacity of forearm vessels in hypertension. Clin Exper Hypertension 1984;A4:968-76.
23. Ogilvie RI. Effects of nifedipine and propranolol on blood flow, venous compliance and blood pressure in essential hypertension. Can Med Assoc J 1986;132:1137-41.
24. Mitenko PA, Ogilvie RI. Rapidly achieved plasma concentrations plateaus with observations on theophylline kinetics. Clin Pharmacol Therap 1972;13:329-25.
25. Mitenko PA, Ogilvie RI. Rational intravenous doses of theophylline. NEJM1973;289:600-3.
26. Ogilvie RI, Esquival M, Burns R. Cardiovascular effects of enprophylline and theophylline in man. Clin Pharmacol Ther 1986;39:395-402.
27. Massie BM, O’Connor C, Metra M, et al. Rolofylline, a selective adenosine A1 receptor antagonist, in acute heart failure. NEJM 2010; 363:1419-28.
28. Ogilvie RI, Nadeau JH, Sitar D. Diazoxide concentration-response relation in hypertension. Hypertension 1982;4:320-4.
29. The Norwegian Study Group. Timolol-induced reduction in mortality and re-infarction in patients surviving acute myocardial infarction. NEJM1981;304:801-7.
30. Achong MR, Piafsky KM, Ogilvie RI. Comparison of cardiac effects of intravenous timolol (MK-950) and propranolol. Clin Pharmacol Ther 1975;18:278-86.
31. Achong MR, Piafsky KM, Ogilvie RI. The duration of cardiac effects of intravenous timolol and propranolol. Clin Pharmacol Ther 1976;19:148-52.
32. MacLeod S, Hamet P, Kaplan H, et al. Antihypertensive Efficacy of twice-daily propranolol. CanMed Assoc J 1979;121:737-40.
33. Larochelle P, Hamet P, Hoffman B, et al. Labetalol in essential hypertension. J Cardiovasc Pharmacol 1980;2:751-9.
34. Nadeau JH, Ogilvie RI, Ruedy J, et al. Acebutolol and hydrochlorothiazide in essential hypertension. Clin Pharmacol Therap 1981; 28:296-301.
35. Ogilvie RI, Hamet P, Kreeft P, et al. Once-daily Dosing of acebutolol in hypertension. J Cardiovasc Pharmacol 1983;5:157-61.
36. Larochelle P, Ogilvie RI. Effective vascular compliance in acute heart failure. Canad. J Physiol Pharmacol 1975;53:129-36.
37. Ogilvie RI. Comparative effects of vasodilator drugs on flow distribution and venous return. Can J Physiol Pharmacol 1985;63:1345-55.
38. Ogilvie RI, Zborowska-Sluis D. Effect of captopril treatment on total and central vascular capacitance in dogs with chronic heart failure. J Cardiovasc Pharmacol 1994; 24:358-64.
39. Ogilvie RI. Vasodilators and the Treatment of Hypertension. In, Principles of Medical Pharmacology. H. Kalant, DM Grant, J. Mitchell ed. Toronto 2007; pp448-457.
40. Tweeddale MG, Ogilvie RI. Antagonism of spironolactone-induced natriuresis by aspirin in man. NEJM1973;289:198-200.
41. Piafsky KM, Sitar DS, Ogilvie RI. Disposition of intravenous theophylline after phenobarbital treatment. Clin Pharmacol Therap 1977;12:409- 14.
42. Esquivel M, Cussenot F, Ogilvie RI, East DS, Shaw D. Interaction of isoxicam with acetylsalicylic acid. Brit J Clin Pharmacol 1984;18:567-71.
43. Levine MAH, Ogilvie RI, Leenen FHH. Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol. Clin Pharmacol Therap 1988; 43:39-48.
44. Dorian P, Strauss M, Cardell C, et al. Digoxincyclosporine interaction; Severe digitalis toxicity after cyclosporine treatment. Clin Investigative Med 1988;11:108-11.
45. Roy LF, East DS, Browning FM, et al. Shortterm effects of calcium antagonists on hemodynamics and cyclosporine pharmacokinetics in heart-transplant and kidneytransplant patients. Clin Pharmacol Therap 1989;657-67.
46. Robieux I, Dorian P, Klein J, et al. The effects of cardiac transplantation and cyclosporine therapy on digoxin pharmacokinetics. J Clin Pharmacol 1991;49:140-3.